Sfoglia per Autore
Impact of Toll-like Receptor 4 (TLR4) chemical modulation by small- molecular antagonists in rare inflammatory-fibrotic diseases
2023 Italia, A; A Franco, A; Romerio, A; Shaik, M; Costa, B; Peri, F; Lovisa, S
Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function
2023 Arici, M; Ferrandi, M; Barassi, P; Hsu, S; Torre, E; Luraghi, A; Ronchi, C; Chang, G; Peri, F; Ferrari, P; Bianchi, G; Rocchetti, M; Zaza, A
Overcoming Challenges in Chemical Glycosylation to Achieve Innovative Vaccine Adjuvants Possessing Enhanced TLR4 Activity
2023 Romerio, A; Franco, A; Shadrick, M; Shaik, M; Artusa, V; Italia, A; Lami, F; Demchenko, A; Peri, F
A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice
2023 Balu, D; Valencia-Olvera, A; Nguyen, A; Patnam, M; York, J; Peri, F; Neumann, F; Ladu, M; Tai, L
Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory
2023 Artusa, V; Calabrone, L; Mortara, L; Peri, F; Bruno, A
Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function
2022 Arici, M; Ferrandi, M; Hsu, S; Torre, E; Barassi, P; Luraghi, A; Ronchi, C; Chang, G; Peri, F; Ferrari, P; Bianchi, G; Rocchetti, M; Zaza, A
A Global Picture of Molecular Changes Associated to LPS Treatment in THP-1 Derived Human Macrophages by Fourier Transform Infrared Microspectroscopy
2022 Ami, D; Franco, A; Artusa, V; Mereghetti, P; Peri, F; Natalello, A
Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure
2022 Luraghi, A; Ferrandi, M; Barassi, P; Arici, M; Hsu, S; Torre, E; Ronchi, C; Romerio, A; Chang, G; Ferrari, P; Bianchi, G; Zaza, A; Rocchetti, M; Peri, F
Green and Roasted Coffee Extracts Inhibit Interferon-β Release in LPS-Stimulated Human Macrophages
2022 Artusa, V; Ciaramelli, C; D’Aloia, A; Facchini, F; Gotri, N; Bruno, A; Costa, B; Palmioli, A; Airoldi, C; Peri, F
NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR
2021 Peri, F; Romerio, A; D'Amato, S
The long-lasting istaroxime metabolite PST3093 stimulates SERCA2a and reverses disease-induced changes in cardiac function
2021 Arici, M; Ferrandi, M; Hsu, S; Torre, E; Barassi, P; Luraghi, A; Ronchi, C; Chang, G; Peri, F; Ferrari, P; Bianchi, G; Rocchetti, M; Zaza, A
Electrospinning for drug delivery applications: A review
2021 Luraghi, A; Peri, F; Moroni, L
Preface
2021 Rossetti, C; Peri, F
The Role of TLR4 in Neural Stem Cells–Mediated Neurogenesis and Neuroinflammation
2021 De Filippis, L; Peri, F
A Highly Sensitive Luminescent Biosensor for the Microvolumetric Detection of the Pseudomonas aeruginosa Siderophore Pyochelin
2021 Visaggio, D; Pirolo, M; Frangipani, E; Lucidi, M; Sorrentino, R; Mitidieri, E; Ungaro, F; Luraghi, A; Peri, F; Visca, P
The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells
2021 Tisi, R; Spinelli, M; Palmioli, A; Airoldi, C; Cazzaniga, P; Besozzi, D; Nobile, M; Mazzoleni, E; Arnhold, S; De Gioia, L; Grandori, R; Peri, F; Vanoni, M; Sacco, E
Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and in Vivo Activity
2021 Facchini, F; Minotti, A; Luraghi, A; Romerio, A; Gotri, N; Matamoros-Recio, A; Iannucci, A; Palmer, C; Wang, G; Ingram, R; Martin-Santamaria, S; Pirianov, G; De Andrea, M; Valvano, M; Peri, F
Synthetic glycolipid-based TLR4 antagonists negatively regulate TRIF-dependent TLR4 signalling in human macrophages
2021 Palmer, C; Facchini, F; Jones, R; Neumann, F; Peri, F; Pirianov, G
Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants
2021 Franco, A; Peri, F
Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview
2020 Romerio, A; Peri, F
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile